结核病：临床试验和新药方案。
Tuberculosis: clinical trials and new drug regimens.
机构信息
aDepartment of Internal Medicine, Chonnam National University Hospital, Gwangju bDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea *Yong-Soo Kwon and Byeong-Ho Jeong contributed equally to the writing of this work.
出版信息
Curr Opin Pulm Med. 2014 May;20(3):280-6. doi: 10.1097/MCP.0000000000000045.
PURPOSE OF REVIEW
Recent advances in the development of new drugs and regimens provide hope that well tolerated, effective, and shorter-duration treatments for tuberculosis (TB) will become available. This review covers the recent trials of new TB drugs and regimens.
RECENT FINDINGS
Moxifloxacin and levofloxacin have equally good efficacy and safety in the early phase of treatment of multidrug-resistant TB (MDR-TB), and linezolid has the potential to cure refractory cases of MDR-TB. Bedaquiline and delamanid may be the best drug candidates for enhancing treatment options for MDR-TB. New chemicals, such as sutezolid, AZD5847, PA-824, SQ109, and BTZ043, show potent activity against Mycobacterium tuberculosis. Late-generation fluoroquinolones in combination with the first-line and second-line anti-TB drugs have been used to shorten the treatment duration in drug-susceptible and MDR-TB.
SUMMARY
New drugs and new combination regimens in clinical trials are expected to increase therapeutic efficacy and shorten treatment duration in both drug-susceptible and drug-resistant TB.
目的综述
新药物和方案的研发进展为耐多药结核病（MDR-TB）提供了更有效、更耐受、疗程更短的治疗希望。本文综述了新的结核病药物和方案的临床试验。
最近发现
莫西沙星和左氧氟沙星在治疗耐多药结核病（MDR-TB）的早期阶段疗效和安全性相当，而利奈唑胺有可能治愈难治性 MDR-TB 病例。贝达喹啉和德拉马尼可能是增强耐多药结核病治疗选择的最佳药物候选物。新型化学物质，如 Sutezolid、AZD5847、PA-824、SQ109 和 BTZ043，对结核分枝杆菌显示出强大的活性。新一代氟喹诺酮类药物与一线和二线抗结核药物联合使用，缩短了药物敏感和耐多药结核病的治疗时间。
总结
临床试验中的新药和新联合方案有望提高治疗效果，缩短耐多药和耐药结核病的治疗时间。
Zotero 插件